VUZI Vuzix Corp. gains 39% Jun 28, 2019

Vuzix Corporation designs, manufactures, markets, and sells wearable display devices in the United States and internationally. The company's products are worn like eyeglasses that enable the user to view video and digital content, such as movies, computer data, the Internet, or video games. Its products include binocular wearable displays that contain two micro displays mounted in a frame attached to eyeglass-style temples or stereo headphones; monocular smart glasses products for the enterprise, industrial, and commercial markets, as well as video headphones; augmented reality products, which provide the user a live, direct or indirect, view of a physical, and real-world environment; and video viewing glasses as mobile displays for entertainment and gaming for on-the-go users, as well as support for stepping into virtual worlds, simulations, and virtual reality gaming. The company sells its products under the Vuzix brand name. Vuzix Corporation offers its products directly to consumers, as well as through specialty retailers, online retailers, distributors, resellers, and Web stores. The company was formerly known as Icuiti Corporation and changed its name to Vuzix Corporation in 2007. Vuzix Corporation was founded in 1997 and is based in West Henrietta, New York.http://www.priceseries.com/trade/VUZI-Vuzix-Corp-stock-gains-39-percent-a-Trade-Record-by-priceSeries-2019061020190628.html

STRM Streamline Health Solutions, Inc. gains 20% Jun 28, 2019

Streamline Health Solutions, Inc. provides health information technology solutions and services for hospitals and health systems in the United States and Canada. It offers computer software-based solutions through its Looking Glass platform, which captures, aggregates, and translates structured and unstructured data to deliver predictive insights to its clients. The company provides patient engagement solutions to assist clients in individual workflows, such as a patient portal, physician referral, patient eligibility and authorization, and patient scheduling, as well as patient payment, including charity management. It also offers patient care solutions that enable healthcare providers to enhance their patient care through individual workflows comprising clinical analytics, operating room management, physician portal, and care coordination; and health information management, coding, and clinical documentation improvement (CDI) solutions, which include Web-based software solutions, such as content management, release of information, computer-assisted coding, CDI, abstracting, and physician query. In addition, the company provides financial management solutions, including accounts receivable management, denials management, claims processing, spend management, and audit management; and custom integration, training, electronic image conversion, and database monitoring services. It sells its solutions and services through direct sales force and reseller partnerships. Streamline Health Solutions, Inc. was founded in 1989 and is based in Atlanta, Georgia.http://www.priceseries.com/trade/STRM-Streamline-Health-Solutions-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2019061220190628.html

ZIOP ZIOPHARM Oncology Inc gains 24% Jun 24, 2019

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon's synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.http://www.priceseries.com/trade/ZIOP-ZIOPHARM-Oncology-Inc-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2019061120190624.html

XON Intrexon Corp. gains 28% Jun 24, 2019

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.http://www.priceseries.com/trade/XON-Intrexon-Corp-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2019061020190624.html

PTN Palatin Technologies, Inc. gains 16% Jun 24, 2019

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refractory hypertension. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.http://www.priceseries.com/trade/PTN-Palatin-Technologies-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019062120190624.html

CVCO Cavco Industries, Inc. gains 23% Jun 24, 2019

Cavco Industries, Inc. engages in the design, production, and retail sale of manufactured homes in the United States. It operates through two segments, Factory-Built Housing and Financial Services. The company markets its manufactured homes under the Cavco Homes, Fleetwood Homes, Palm Harbor Homes, Fairmont Homes, and Chariot Eagle brands. It also produces modular homes, including single and multi-section/modular ranch-style dwellings, split-level homes, Cape Cod style homes, two and three story homes, and multi-family units under the Nationwide Homes brand name. In addition, the company builds park model RVs and vacation cabins, as well as systems-built commercial structures, such as apartment buildings, condominiums, hotels, workforce housing, schools, and housing for U.S. military troops. Further, it offers conforming mortgages, non-conforming mortgages, and chattel loans to purchasers factory-built and site-built homes; and property and casualty insurance to owners of manufactured homes. As of April 2, 2016, the company owned and operated a network of 45 retail centers located in Oregon, Arizona, New Mexico, Texas, Oklahoma, Louisiana, Virginia, North Carolina, and Florida. It also distributes its homes through a network of independent distribution points in 44 states in the United States, Canada, Japan, and Mexico, as well as through planned community operators and residential developers. The company was founded in 1965 and is headquartered in Phoenix, Arizona.http://www.priceseries.com/trade/CVCO-Cavco-Industries-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2019052020190624.html

CIEN Ciena Corp. gains 20% Jun 24, 2019

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company's Networking Platforms segment offers hardware networking solutions optimized for the convergence of coherent optical transport, optical transport network switching, and packet switching. Its products include 6500 Packet-Optical Platform and the 5430 Reconfigurable Switching System, Waveserver stackable interconnect system, CoreDirector Multiservice Optical Switches, and OTN configuration for the 5410 Reconfigurable Switching System, as well as Z-Series Packet-Optical Platform; 3000 family of service delivery switches and service aggregation switches, and the 5000 family of service aggregation switches, as well as 8700 Packetwave Platform and the Ethernet packet configuration for the 5410 Service Aggregation Switch; and 4200 Advanced Services Platform, Corestream 5100/5200 Advanced Services Platform, Common Photonic Layer, and 6100 Multiservice Optical Platform. This segment also sells operating system software and enhanced software features embedded in each of these products. The company's Software and Software-Related Services segment offers network management solutions, including the OneControl Unified Management System, ON-Center Network & Service Management Suite, Ethernet Services Manager, Optical Suite Release, and Planet Operate; and Blue Planet network virtualization, service orchestration, and network management software platform, as well as related installation, support, and consulting services. Its Global Services segment provides consulting and network design, installation and deployment, maintenance support, and training services. The company sells its products through direct and indirect sales channels to network operators. Ciena Corporation was founded in 1992 and is headquartered in Hanover, Maryland.http://www.priceseries.com/trade/CIEN-Ciena-Corp-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2019060420190624.html

ROKU Roku, Inc. gains 68% Jun 21, 2019

http://www.priceseries.com/trade/ROKU-Roku-Inc-stock-gains-68-percent-a-Trade-Record-by-priceSeries-2019042520190621.html

BYSI BeyondSpring Inc. gains 28% Jun 21, 2019

N/Ahttp://www.priceseries.com/trade/BYSI-BeyondSpring-Inc-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2019060720190621.html

IOVA Iovance Biotherapeutics, Inc. gains 62% Jun 4, 2019

Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; and PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is headquartered in New York, New York.http://www.priceseries.com/trade/IOVA-Iovance-Biotherapeutics-Inc-stock-gains-62-percent-a-Trade-Record-by-priceSeries-2019051520190604.html